Advertise on podcast: DoctorPodcasts || Cykiert Files

Are you experiencing relationship troubles? It's not because the love is gone, it's because of BURNOUT! Watch for expert remedies (not AI), plus the paraphrasing rule that saves arguments nearly every time! Dr. Mindy DeSeta of https://Insight-Miami.com has great, expert advice.

Leading breast cancer specialist and medical oncologist, Robert Wesolowski, M.D. of the Ohio State University Comprehensive Cancer Center breaks down the latest breakthroughs in breast cancer treatment, including the newly FDA-approved targeted drug REVTORPYK (gedatolisib / Celcuity), how genetic markers like BRCA1 & BRCA2 guide care, and what the future of AI looks like in oncology.🔔 Subscribe to DoctorPodcasts: Don't forget to like this DoctorPodcasts Episode 171 video, leave a comment with your thoughts or questions, and share this episode with anyone navigating breast cancer treatment!⏱️ TIMESTAMPS & CHAPTERS:00:00 - Introduction & Meet Dr. Robert Wesolowski01:35 - Breast Cancer Statistics & Trends in Younger Populations04:03 - The 3 Main Subtypes: HR+, HER2+, & Triple-Negative06:50 - How Survival Rates & Outlook Have Transformed07:46 - BRCA1 vs. BRCA2 Genes: What Are the Risks?09:43 - Who Should Get Genetic Testing & Counseling?11:07 - Surgery vs. Radiation vs. Chemotherapy Decision Making14:09 - The Power of Neoadjuvant Chemotherapy & Targeted Drugs16:24 - REVTORPYK Breakthrough: Mechanism, Clinical Trial Data & FDA Approval19:17 - Administration Schedule & Managing Side Effects21:25 - How AI Is Revolutionizing Global Breast Cancer Care23:18 - Closing Remarks⚠️ Medical Disclaimer:This video podcast is for educational and informational purposes only and does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician regarding a medical condition.#BreastCancer #Oncology #REVTORPYK #CancerResearch #BRCA #WomensHealth #CancerTreatment #cancer #Cykiert #Celcuity #DoctorPodcasts

New FDA-Accelerated approval for BEQALZI pill to treat Mantle Cell Lymphoma cancers that are resistant to or recur with older treatments. Watch video podcast with expert, Michael Wang, M.D. , who explains the disease and BEQALZI made by BeOne Medicines.DoctorPodcasts EPISODE 170 Timeline/ Chapters: - Introduction & Welcome - Meet Dr. Michael Wang (MD Anderson Cancer Center) - What Is Lymphoma? (Liquid Cancers vs. Solid Tumors) - What Makes Mantle Cell Lymphoma Unique & Difficult to Treat? - Who Gets Mantle Cell Lymphoma? (Demographics & Risk Factors) - Symptoms of Mantle Cell Lymphoma - How MCL Is Diagnosed: Biopsies, Markers & Flow Cytometry - The Evolution of Treatment: Moving Beyond Chemotherapy - Targeted Therapies: BTK Inhibitors & CAR T-Cell Therapy - Understanding BCL-2 Inhibitors in Cancer Mitochondria - BEQALZI (Sonrotoclax): Breakthrough BCL-2 Inhibitor - What Is FDA Accelerated Approval? - BEQALZI Clinical Trial Results & Response Rates - Dosing & Treatment Duration (Once-Daily Pill) - Availability & Sonrotoclax vs. Venetoclax - BeOne Medicines & Global Collaboration - Conclusion & Closing Remarks

What is ZIIHERA, and how is this newly FDA-approved targeted therapy transforming the treatment of advanced HER2-positive gastroesophageal cancer? In this episode 168 of DoctorPodcasts: Cykiert Files, host Dr. Robert Cykiert is joined by two world-renowned oncology experts: • Dr. Geoffrey Ku – Associate Attending Physician, Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center (MSKCC) & Phase 3 trial investigator. • Dr. Robert Iannone – Executive Vice President, Global Head of R&D, and Chief Medical Officer at Jazz Pharmaceuticals. Together, they break down the groundbreaking science behind ZIIHERA, the landmark HORIZON-GEA-01 Phase 3 trial results, managing treatment side effects (including diarrhea prophylaxis), biomarker testing (HER2 & PD-L1), and what this means for patients with metastatic and locally advanced esophageal, GE junction, and gastric adenocarcinoma cancers. 📌 In This Episode, You’ll Learn: • What gastroesophageal adenocarcinoma (GEJ cancer) is and key risk factors (acid reflux, Barrett’s esophagus, H. pylori). • How ZIIHERA’s unique bispecific HER2 antibody mechanism differs from standard therapies like Herceptin (trastuzumab). • Key survival and progression-free survival findings from the HORIZON-GEA-01 Phase 3 study. • Why ZIIHERA combined with immunotherapy benefits patients regardless of PD-L1 status. • Essential clinical guidance on managing and preventing GI side effects. • Why comprehensive biomarker and HER2 testing is vital for every patient. ⏱️ TIMELINE / CHAPTERS: 00:00 - Introduction to Gastroesophageal Cancer & ZIIHERA 00:43 - Introducing Dr. Geoffrey Ku (MSKCC) & Dr. Robert Iannone (Jazz Pharmaceuticals) 02:16 - What is Gastroesophageal Adenocarcinoma (GE Junction & Stomach Cancer)? 03:27 - Risk Factors: Acid Reflux, Barrett’s Esophagus, Obesity & H. Pylori 06:43 - Why Esophageal and Stomach Cancers Are Often Diagnosed Late 09:17 - Understanding HER2-Positive Cancer & Key Biomarkers (PD-L1, MMR, Claudin 18.2) 12:25 - Evolution of 1st-Line Treatment: Chemo, Trastuzumab & Immunotherapy 14:06 - How ZIIHERA (Zanidatamab) Was Developed & Mechanism of Action 17:03 - Biliary Tract Cancer Approval to Gastroesophageal Phase 3 Trials 19:30 - HORIZON-GEA-01 Phase 3 Trial Design & FDA Approval Indications 20:56 - Efficacy Across PD-L1 Positive and Negative Patients 22:20 - Metastatic vs. Locally Advanced Disease & Potential Curative Setting 26:13 - Safety Profile & Managing Side Effects (Diarrhea Prophylaxis Protocols) 31:08 - Cardiac Monitoring & Drug Tolerability 31:47 - Dosing, Administration Route & Treatment Duration 33:28 - Overall Survival & Progression-Free Survival Data Breakdown 39:16 - Patient Quality of Life During Treatment 40:17 - Encouragement for Patients & Families Considering Targeted Therapy 44:06 - Nationwide Availability & Global Regulatory Status (Project Orbis) 46:11 - The Critical Importance of Routine HER2 Biomarker Testing 48:11 - Future Applications of ZIIHERA & Jazz Pharmaceuticals Oncology Pipeline 51:09 - Concluding Remarks & Summary 🔔 Please subscribe to DoctorPodcasts: Cykiert Files for expert discussions on medical breakthroughs, clinical trials, and healthcare innovations. Disclaimer: This video podcast is for educational and informational purposes only and does not constitute personalized medical advice. Please consult your physician or qualified healthcare provider regarding specific medical conditions or treatments. #EsophagealCancer #ZIIHERA #StomachCancer #Oncology #CancerResearch #HER2Positive #Immunotherapy #CancerBreakthrough #MedicalPodcast #JazzPharmaceuticals #Cykiert #DoctorPodcasts

In this episode 167 of DoctorPodcasts: Cykiert Files, we explore the groundbreaking advancements in cancer therapy and how Sanofi’s new FDA-approved treatment Sarclisa Escena via a CirCLIQ On‑Body Injector https://pro.campus.sanofi/us/products/sarclisa is revolutionizing multiple myeloma patient care and improving patients' quality of life. It's also benefiting physician and healthcare provider efficiencies while reducing healthcare costs.Learn how this targeted therapy works from Mayo Clinic Multiple Myeloma expert, Sikander Ailawadhi, M.D., https://www.mayoclinic.org/biographies/ailawadhi-sikander-m-d/bio-20087330, the clinical data behind its approval, and what this means for patients, oncologists, and the future of oncology treatments.⏱️ TIMESTAMPS / CHAPTERS00:00 - Introduction to Multiple Myeloma & Recent Breakthroughs03:15 - What is Multiple Myeloma? (Disease Overview)07:45 - The Science Behind Sanofi’s FDA-Approved Treatment12:30 - Key Clinical Trial Results & Patient Outcomes18:10 - How This Treatment Compares to Standard of Care23:40 - Future Outlook for Multiple Myeloma Therapies28:10 - Final Thoughts & Summary💬 JOIN THE CONVERSATIONHave questions about this new FDA approval or current cancer treatment advances? Drop your thoughts or questions in the comments below!👍 Like this video if you found it informative, and Subscribe to DoctorPodcasts: Cykiert Files for in-depth medical discussions, expert interviews, and healthcare breakthroughs.🔔 DISCLAIMERThe information provided in this video podcast is for educational and informational purposes only and is not intended as medical advice. Always consult a qualified healthcare professional regarding any medical condition or treatment.🏷️ HASHTAGS#MultipleMyeloma #CancerResearch #Oncology #FDAApproval #CancerTreatment #MedicalBreakthrough #DoctorPodcasts #CirCLIQ #On-Body Injector#Sanofi #Sarclisa #Sarclisa Escena #Cykiert

Colon-rectal cancer is one of the leading causes of cancer-related deaths, yet it is highly treatable and preventable when detected early. Three world-renowned experts discuss the latest breakthroughs in non-invasive colon cancer screening, including at-home @Cologuard stool DNA tests and newly FDA-approved @Freenome blood tests.00:00 - Introduction: The Power of Non-Invasive Screening 02:36 - Welcome & Meet the Expert Panel 06:31 - Colorectal Cancer Trends & The Rise in Under-50 Cases 08:30 - Early Warning Signs vs. Asymptomatic Colon Cancer 09:09 - Why Screening Guidelines Lowered the Age to 45 10:40 - Why Do People Delay or Avoid Colonoscopies? 12:45 - What Is Cologuard & Multi-Target Stool DNA Testing? 15:10 - Who Is Eligible for Non-Invasive Screening? 16:04 - Step-by-Step: The At-Home Cologuard Experience 17:36 - Do At-Home Tests Replace a Colonoscopy? 18:47 - Accuracy & Clinical Data 20:23 - Patient Adherence Rates & Common Misconceptions 22:58 - Riley Ennis & The Story Behind Freenome 24:05 - How SimpleScreen CRC Uses Multiomics & AI 25:34 - SimpleScreen CRC Accuracy & PREEMPT CRC Trial Data 27:02 - Where Blood Tests Fit in the Screening Cascade 28:24 - Overview of New FDA-Approved Non-Invasive Options 29:07 - Cologuard vs. Cologuard Plus: What Changed? 30:05 - Can Stool and Blood Tests Be Combined? 31:22 - Awareness Campaigns & Educating the Public 33:06 - The Future of Colonoscopies & Early Detection 34:43 - Beyond CRC: Multi-Cancer Early Detection (Lung & Pancreas) 36:26 - Insurance & Medicare Coverage Explained 38:52 - Final Takeaways & Advice for Patients

In this episode 165 of the DoctorPodcasts show, host Dr. Robert Cykiert video interviews board-certified plastic surgeon Dr. Nirmal Nathan, founder of the Nathan Clinic in Miami, Florida to break down the massive cultural and medical shifts defining modern cosmetic surgery. From the rapid rise of GLP-1 weight loss drugs like Ozempic, Wegovy, Mounjaro, and Zepbound to the reality behind "Ozempic Face, Skin and Body," Dr. Nathan pulls back the curtain on how plastic surgeons address sagging skin without causing the dreaded "wind tunnel" look. They also dive into why millions of men are turning to cosmetic surgery in the post-COVID "Zoom Boom," the truth about secret $100K celebrity procedures, and the real life-threatening dangers of low-regulated medical tourism overseas. Whether you’re curious about deep plane facelifts, the evolution of social media beauty standards, or how conditions like diabetes impact surgical safety, this deep-dive interview provides expert clinical insights you won't find anywhere else. Subscribe to DoctorPodcasts for more exclusive medical interviews, health trends, and expert insights:⏳ TIMESTAMPS 0:00 - Introduction & Meet Top Plastic Surgeon Dr. Nurmal Nathan2:48 - The Family Legacy: Growing Up Watching Facial Reconstruction5:01 - Inside the Training of a Top Plastic Surgeon (UCSF & Miami Volume)7:05 - From Nip/Tuck to the Kardashians: What is Driving the Plastic Surgery Boom?8:14 - The COVID "Zoom Boom" & The Massive Rise of Men's Plastic Surgery9:34 - Celebrity Plastic Surgery vs. Social Media Influence: What Sets the Trends?11:05 - The Truth About $100k "Secret" Procedures & Plastic Surgery Arbitrage12:48 - The Real Dangers of Medical Tourism (Botched Work Overseas)15:28 - The GLP-1 Weight Loss Revolution (Ozempic, Wegovy, Mounjaro)17:03 - Understanding "Ozempic Face" & Advanced Facial Aging18:26 - How Deep Plane Facelifts Tighten Sagging Skin Safely (Avoiding the Wind Tunnel Look)19:03 - The "Goldilocks Sweet Spot": When Is It Safe to Get Surgery After Weight Loss?21:13 - Medical Optimization: Why a Hemoglobin A1C Under 7 Matters for Healing

High triglycerides over 500 can trigger life-threatening acute pancreatitis. Harvard and Brigham cardiologist Dr. Brian Bergmark explains severe hypertriglyceridemia, familial chylomicronemia syndrome, and the FDA-expanded use of Tryngolza from Ionis. In the trials, triglycerides fell about 50–70% and acute pancreatitis dropped 85%. We cover how triglycerides differ from LDL cholesterol, who needs fasting labs, why statins barely move very high TGs, how ApoC3 antisense works, and who is a candidate for treatment. Video Timestamps 00:00 - What causes high triglycerides? Genetics vs. lifestyle 01:44 - Introduction: Dr. Robert Cykiert welcomes Harvard Cardiologist Dr. Brian Bergmark 04:05 - What are triglycerides and why does the body need them?04:38 - High triglycerides vs. cholesterol: The "Amazon Truck" analogy 06:28 - Severe health risks: Cardiovascular disease and acute pancreatitis 08:57 - How to test your triglycerides: Routine blood panels and fasting rules 09:48 - What is a normal triglyceride level vs. the danger zone? 10:37 - How high triglycerides cause pancreatitis, brain fog, and abdominal pain 12:59 - The relationship between triglycerides below 500 mg/dL and stroke risk 14:44 - Why very high triglycerides can actually lead to lower LDL cholesterol 16:31 - How the new drug Tryngolza works to break down fats in the blood 17:48 - FDA approval timeline and clinical trial results: 85% risk reduction 20:35 - Who is a good candidate for a once-monthly Tryngolza injection? 21:38 - Potential side effects: Skin reactions, HbA1c changes, and liver fat monitoring 24:22 - Lifestyle modifications and diet changes vs. immediate prescription medication Host: Dr. Robert #Cykiert | Guest: Dr. Brian BergmarkFollow #DoctorPodcasts | Episode 164 #triglycerides #cardiology #Tryngolza #cholesterol #heart

First kidney and liver tissues ever bioprinted in space — and they just returned to Earth on a SpaceX Dragon capsule in June 2026.In this exclusive Episode 163 of the DoctorPodcasts Show, world-leading regenerative medicine pioneer Anthony Atala, M.D. (Director, Wake Forest Institute for Regenerative Medicine) reveals how microgravity on the International Space Station produces healthier, better-organized tissues than on Earth — and how SpaceX’s frequent, reusable cargo flights have transformed the field from rare opportunities into something “almost like booking an airline trip” says Robert Cykiert, M.D. of #DoctorPodcasts.Watch the full video podcast interview to learn:• Why growing tissues in space solves major Earth-based bioprinting challenges• How astronauts use Auxilium’s onboard bioprinter to create the first-ever space-printed kidney & liver tissues• The role of patient-specific cells (no rejection risk)• The path from small tissue samples to future transplantable organs• Radiation protection strategies and organ “avatars” for deep-space travel• How these breakthroughs are already accelerating regenerative medicine for patients on EarthTimestamps:0:00 – SpaceX Dragon returns the samples & why frequent cargo flights matter1:14 – Episode intro & organ shortage crisis2:10 – Meet Dr. Anthony Atala3:39 – What is regenerative medicine?4:16 – From lab-grown bladders to 3D bioprinting5:33 – Why bioprinting is a game-changer (scalability, reproducibility, cost)6:20 – The toughest hurdles for solid organs (kidney & liver)7:14 – Sending bioprinted tissues to the ISS8:44 – How bioprinting actually works (simple explanation)10:35 – Why microgravity is better for growing tissues12:09 – Who cares for the tissues in space?13:14 – Stem cells vs donor cells14:00 – “Diet” for cells in space15:07 – Printing blood vessels with kidney tissue16:00 – Do we need a whole kidney… or just “refill the tank”?17:39 – Historic first: kidney & liver tissues printed in space19:21 – SpaceX’s game-changing frequent returns20:35 – Working with NASA, Axiom, Auxilium, CASIS & the full team22:13 – When will we have transplantable space-grown organs?23:41 – Patient’s own cells = no rejection24:22 – Brain organoids, lungs & more26:18 – Protecting tissues from space radiation28:10 – What excites Dr. Atala most + message to the publicDr. Anthony Atala is a true pioneer: 18 technologies already used in patients, 900+ peer-reviewed papers, 300+ patents, National Academy of Medicine member, and twice named to TIME’s Top 10 Medical Breakthroughs.Subscribe for more exclusive interviews with the world’s leading physicians and scientists advancing healthcare.👍 Like • 💬 Comment • 🔁 Share if this gives you hope for the future of organ transplants#SpaceX #Bioprinting #RegenerativeMedicine #AnthonyAtala #SpaceMedicine #3DBioprinting #Kidney #Liver #ISS #NASA #AxiomSpace #OrganTransplant #Microgravity #WakeForest #Cykiert #SpaceXDragon #FirstInSpace #FutureOfMedicine #TissueEngineering

Is coffee good for your heart, brain and body — or should you cut back on caffeine ? In this DoctorPodcasts episode 162 we talk with top cardiologist, Gregory Marcus, M.D. (UCSF), the lead author of the brand-new American Heart Association (AHA) scientific statement on caffeine and cardiovascular disease. Dr. Marcus breaks down the latest evidence on coffee, caffeine, energy drinks, AFib, heart attacks, stroke, heart failure, diabetes, and more. You’ll learn:• How many cups of coffee are considered safe for most adults• Why moderate coffee drinking may actually lower risk of certain heart conditions• The big difference between coffee and high-dose energy drinks• What the science says about caffeine and atrial fibrillation• Practical takeaways for everyday coffee drinkers Clear, evidence-based answers from the doctor who led the AHA review. Watch or listen now and decide for yourself how your daily cup(s) fit into a heart-healthy life.

A new FDA-approved oral antiviral may offer a new option for people exposed to COVID-19.In this episode 161 of the DoctorPodcasts Show, Dr. Robert Cykiert interviews two physicians from the Shionogi Pharmaceutical Company who discuss XOCOVA®, its recent FDA approval, how it works, who may be eligible, and the clinical trial results behind the approval.Joining us are:Florin Draica, MD — Head of U.S. Medical Affairs at Shionogi Pharmaceutical CompanySimon Portsmouth, MD — Senior Vice President and Head of Clinical Development at Shionogi Pharmaceutical CompanyIn this interview, we discuss:• Why COVID-19 is still a health concern in 2026• What happens after you are exposed to SARS-CoV-2• What is XOCOVA?• How does this new COVID antiviral work?• What is a main protease inhibitor?• How is XOCOVA different from previous COVID treatments?• Is XOCOVA for people who already have COVID—or people exposed to someone with COVID?• What did the Phase 3 SCORPIO-PEP clinical trial find?• Why did the study report a 67% reduction in symptomatic COVID-19 through Day 10 in its primary analysis?• How did XOCOVA perform among people with risk factors for severe COVID?• Does XOCOVA replace COVID vaccination?• How soon after COVID exposure should someone contact a healthcare professional?• What are the potential side effects and medication interactions?• Who should and should not take XOCOVA?• Why pregnant or breastfeeding patients should discuss alternatives with their healthcare professional• Could main protease inhibitor technology help prepare us for future coronavirus outbreaks or pandemics?The discussion emphasizes that XOCOVA is intended for people who have been exposed to COVID-19 and are not yet sick, and that treatment decisions should be made with a qualified healthcare professional. The interview discusses taking action promptly after exposure, including the timeframe discussed by the guests.The guests also explain why XOCOVA is not intended to replace vaccination, but may provide another approach following exposure to COVID-19.Subscribe to DoctorPodcasts for interviews with leading physicians, scientists, researchers, and experts discussing the latest developments in medicine, health, science, technology, and public health.👍 If you found this interview informative, please LIKE the video, SUBSCRIBE, and turn on notifications for future interviews.Important medical disclaimerThis video is for educational and informational purposes only and is not individual medical advice. XOCOVA is a prescription medication. Whether it is appropriate for a particular person depends on individual circumstances, medical history, medications, and other factors. Please consult a qualified healthcare professional regarding diagnosis and treatment decisions.#XOCOVA #Ensitrelvir #COVID19 #COVID #COVIDPrevention #Antiviral #FDAApproved #Coronavirus #SARSCoV2 #COVIDTreatment #PublicHealth #MedicalPodcast #Healthcare #DrPodcast #Shionogi

LIPFENDRA is a brand-new oral cholesterol pill about to change everything for heart attack and stroke prevention. In this must-watch episode 160 of DoctorPodcasts, host Dr. Robert Cykiert discusses cholesterol dangers and treatments with two of the world’s leading cardiologists and lipid experts — Dr. Norman Lepor (Cedars-Sinai, UCLA) and Dr. Christy Ballantyne (Baylor College of Medicine). Watch this deep dive into LIPFENDRA (enlicitide), the first oral PCSK9 inhibitor just approved by the FDA. They break down: • Why LDL cholesterol is the #1 driver of heart attacks and strokes (1.5 million U.S. deaths yearly) • Genetics vs lifestyle: why some people still have sky-high cholesterol on perfect diets • Exact LDL targets based on your risk (and why “normal” on lab reports is often too high) • How Lipfendra works differently from injectable cholesterol medications, Repatha, Praluent, Leqvio • Real efficacy (up to ~60% LDL reduction), safety data, side effects, cost, and who should take it • When the big cardiovascular outcomes trial results are coming. If you or a loved one has high cholesterol, familial hypercholesterolemia, statin intolerance, injection phobia or just wants the latest breakthrough in heart disease prevention, this conversation is essential. Like, subscribe, and share to help more people protect their hearts, brains and other organs! Full Timeline: 0:00 – Welcome to DoctorPodcasts Episode 160 0:33 – Why cholesterol is a top cause of heart attacks & strokes 0:51 – Introducing world experts Dr. Norman Leapor & Dr. Christy Ballantyne 2:38 – What exactly is cholesterol and why does the body need it? 3:58 – How high LDL damages arteries and builds deadly plaque 5:18 – LDL vs HDL vs triglycerides vs Lipoprotein(a) explained 7:00 – Why some people have high cholesterol even on a perfect diet (genetics) 9:17 – When should you start checking cholesterol & advanced tests (Lp(a), ApoB, hs-CRP)? 12:14 – Familial hypercholesterolemia: how common is it and what to do 15:20 – What are truly safe LDL cholesterol goals today? 17:24 – How effective are diet, exercise & lifestyle for genetic high cholesterol? 19:28 – Which other arteries does high cholesterol clog (brain, legs, etc.)? 20:28 – How statins (Lipitor, Crestor) work and why they’re still first-line 22:45 – Why many patients need more than just a statin 24:49 – PCSK9 inhibitors: the injectable game-changers so far 25:55 – Deep dive into Lipfendra: the new oral PCSK9 inhibitor pill 27:57 – Key advantages of the oral pill vs injections (convenience, adherence, storage) 29:41 – When doctors will prescribe Lipfendra (add-on or monotherapy) 31:23 – Perfect for patients who can’t tolerate statins or hate injections 32:28 – Side effects and overall safety profile from the trials 34:04 – Who should not take Lipfendra (contraindications) 34:39 – Cost and insurance coverage expectations 35:33 – How fast does Lipfendra lower LDL and how long does the effect last? 36:48 – Is it as effective as injectable PCSK9 inhibitors like Repatha? 38:03 – Will Lipfendra be a true game-changer? 39:13 – Cardiovascular outcomes data: do these drugs actually prevent heart attacks & death? 42:04 – Working with Merck on the trials and when outcomes results arrive 44:56 – Will AI speed up future cholesterol drug discovery? 46:33 – Final thoughts and thank you #Lipfendra #Cholesterol #PCSK9 #HeartHealth #LDL #Cardiology #HeartAttackPrevention #StrokePrevention #NewCholesterolDrug #FDAApproved #DoctorPodcasts #Cykiert #Stroke #Dementia Please LIKE, Subscribe, Share for more expert interviews on the latest medical breakthroughs that can save lives!

Today we dive into two rare but life-disrupting sleep disorders: narcolepsy and idiopathic hypersomnia. People with these conditions don’t just feel tired — they can fall asleep suddenly while driving, talking, or working, or sleep 11+ hours and still feel completely unrefreshed with intense brain fog and sleep drunkenness. Our guest is world-renowned sleep expert Dr. Logan Schneider, board-certified neurologist and sleep medicine specialist, Adjunct Clinical Associate Professor at Stanford University, and Clinical Lead for Sleep Health at Google. We cover causes (including the loss of the brain chemical orexin/hypocretin), symptoms like cataplexy, diagnosis, the only FDA-approved medication for idiopathic hypersomnia (Xywav), made by Jazz Pharmaceuticals @JazzPharma, lifestyle strategies, common myths, and how to find the right specialist. Timestamps: 0:00 – Introduction & episode overview 1:07 – Meet Dr. Logan Schneider 2:06 – What are sleep disorders and why they matter 3:12 – How common is excessive daytime sleepiness? 5:28 – What is narcolepsy and its main symptoms 6:55 – Sleep attacks and the danger of falling asleep while driving 8:04 – Type 1 narcolepsy: the orexin/hypocretin deficiency 10:25 – Is it autoimmune? What triggers it? 10:29 – How is narcolepsy diagnosed? 12:10 – Narcolepsy Type 2 explained 13:42 – What is cataplexy and REM sleep? 15:07 – Who gets narcolepsy (age & gender) 16:55 – Idiopathic hypersomnia: how it differs from narcolepsy 18:24 – Sleeping 9–11 hours and still exhausted 19:24 – Brain fog and “sleep drunkenness” 21:06 – Does coffee help these disorders? 22:39 – Xywav (low-sodium oxybate): how it works for both conditions 26:32 – Why the low-sodium version matters for heart health 28:56 – REMS program and why it’s a controlled substance 31:45 – Who is a candidate for Xywav? 35:33 – Lifestyle tips and support strategies 37:02 – Common misconceptions about these disorders 40:08 – Do you need a sleep study before treatment? 42:10 – Who can prescribe Xywav? 44:14 – How to find a sleep specialist near you 45:50 – Final message: “Sleepiness is red alert” Subscribe for more expert medical interviews! #Narcolepsy #IdiopathicHypersomnia #SleepDisorders #ExcessiveDaytimeSleepiness #Cataplexy #Xywav #SleepMedicine #BrainFog #Hypersomnia #NarcolepsyAwareness #SleepHealth #DoctorPodcasts #Cykiert #sleep

CRISPR gene editing is no longer science fiction — it’s an FDA-approved treatment transforming lives with sickle cell disease and beta-thalassemia. In this episode of the DoctorPodcasts, host Dr. Robert Cykiert sits down with Dr. Akshay Sharma, Associate Member at St. Jude Children’s Research Hospital and a leading expert in gene therapy and bone marrow transplantation. Dr. Sharma was involved in the clinical trials that led to the approval of Casgevy. Discover how a single DNA edit can raise fetal hemoglobin, stop painful crises, and potentially free patients from lifelong transfusions and organ damage. Learn the real differences between gene therapy and traditional bone marrow transplant, the full treatment timeline, risks (including busulfan chemotherapy), expansion to younger patients, and how AI could accelerate the next generation of cures. This is one of the most important medical breakthroughs of our time. Timeline / Chapters: 0:00 – Introduction & Guest Welcome 2:16 – What is Sickle Cell Disease? The Genetic Defect Explained 5:37 – Inheritance Pattern & How Many People Are Affected 7:04 – Sickle Cell Trait vs. Disease 7:50 – Historical Treatments: Supportive Care, Hydroxyurea & More 12:23 – Bone Marrow Transplant History (First Success at St. Jude in 1983) 13:27 – What is Beta-Thalassemia? 15:40 – How Casgevy Differs from Transfusions & Transplants 20:25 – How CRISPR Gene Editing Works (The Molecular Scissors) 25:48 – Clinical Trials, FDA Approval (Dec 2023) & Age Expansion 30:36 – Treating Young Children: Long-Term Outlook 34:54 – Full Treatment Timeline (9–12 Months) 37:12 – Role of AI in Future Gene Therapies 39:35 – Closing Thoughts #Casgevy, #CRISPR, #sickle #thalassemia, #gene #hemoglobin, #bonemarrowtransplant, , , , #Vertex #CRISPR #DNA #Doctorpodcasts #Cykiert Subscribe for more expert interviews on breakthrough medical treatments. Like, share, and comment with your questions!

🎬Welcome to Episode 157 of the DoctorPodcasts Show! In this episode, host Dr. Robert Cykiert interviews board-certified ophthalmologist and oculoplastic surgeon Dr. Amy Patel Jain, M.D. to discuss a condition affecting thousands of people every day: Thyroid Eye Disease (TED). As a co-investigator in pivotal clinical trials, Dr. Patel Jain shares her deep expertise on how TED impacts patients' eyes and quality of life. We dive into traditional surgical treatments like orbital decompression, the paradigm shift brought on by #Tepezza, and breaking news regarding the June 2026 FDA approval of a brand-new five-infusion targeted biologic treatment: #Lumvoa.If you or a loved one are navigating the challenges of this autoimmune condition, this deep-dive interview offers the clinical insights and treatment options you need to know. Don't forget to SUBSCRIBE, FOLLOW, LIKE, and REPOST to help us spread awareness!⏳ Video Timeline (Chapters) 0:00 — Introduction to Episode 157 & Guest Dr. Amy Patel Jain 2:02 — What is Thyroid Eye Disease (TED) and How Does it Affect the Eyes? 3:26 — TED vs. Graves' Disease: Can You Have TED Without an Active Thyroid Problem? 4:21 — What Causes TED? The Role of TSH and IGF-1R Receptors5:08 — Who is at Risk? Demographics, Genetics, and the Impact of Smoking 7:10 — How Many People in the USA Are Affected by TED? 7:24 — Types of TED: Acute vs. Chronic and Active vs. Inactive Inflammation 10:05 — How TED Affects Patient Quality of Life, Mental Health, and Daily Functioning 11:19 — Traditional TED Treatments: Steroids, Radiation, and Multi-Stage Surgery 13:25 — How Orbital Decompression Surgery Works (The "Ice Cream Cone" Analogy) 15:25 — The Impact of Tepezza: A Paradigm Shift in Medical Treatment 16:24 — Breaking News: How the New Drug Lumvoa Works (Mechanism of Action) 17:33 — Lumvoa vs. Tepezza: Comparing Infusion Times, Frequency, and Treatment Burden 18:35 — Clinical Results: How Quickly Do Patients See Results with Lumvoa? 19:13 — Why TED Causes Diplopia (Double Vision) & Asymmetric Muscle Expansion 20:39 — Main Side Effects and Clinical Considerations (Hypoglycemia, Hearing Changes, IBD) 22:19 — Who is the Ideal Candidate for Lumvoa & Navigating the Viridian Cares Program 24:18 — Will Biologics Reduce the Need for Severe Orbital Decompression Surgeries? 25:42 — Outro & Closing Remarks 🏷️ #ThyroidEyeDisease #TED #Lumvoa #Tepezza #GravesDisease #BulgingEyes #Ophthalmology #AutoimmuneDisease #DoubleVision #ThyroidAwareness #DoctorPodcastsShow #proptosis #exophthalmos Medical Disclaimer: This video is for informational and educational purposes only and does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.